| Mr Barry C Ginsburg, MD | |
|
972 Montclair Rd, Ste 100, Birmingham, AL 35213 | |
| (205) 592-4880 | |
| (205) 592-3999 |
| Full Name | Mr Barry C Ginsburg |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 49 Years |
| Location | 972 Montclair Rd, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790769438 | NPI | - | NPPES |
| 252816 | Medicaid | AL | |
| C71858 | Medicaid | AL |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alabama Dermatology And Rejuvenation Center Pc | 1759769532 | 3 |
News Archive
The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.
The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.
Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
The administration announces that almost 2.8 million people have saved an average $677, because the law is closing the prescription drug doughnut hole.
Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world's leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.
› Verified 4 days ago
| Entity Name | Barry C Ginsburg Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689284655 PECOS PAC ID: 0749695625 Enrollment ID: O20210301000100 |
News Archive
The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.
The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.
Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
The administration announces that almost 2.8 million people have saved an average $677, because the law is closing the prescription drug doughnut hole.
Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world's leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.
› Verified 4 days ago
| Entity Name | Alabama Dermatology And Rejuvenation Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386381614 PECOS PAC ID: 1759769532 Enrollment ID: O20220607001853 |
News Archive
The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.
The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.
Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
The administration announces that almost 2.8 million people have saved an average $677, because the law is closing the prescription drug doughnut hole.
Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world's leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Barry C Ginsburg, MD 972 Montclair Rd, Ste 100, Birmingham, AL 35213-1203 Ph: (205) 592-4880 | Mr Barry C Ginsburg, MD 972 Montclair Rd, Ste 100, Birmingham, AL 35213 Ph: (205) 592-4880 |
News Archive
The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.
The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.
Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
The administration announces that almost 2.8 million people have saved an average $677, because the law is closing the prescription drug doughnut hole.
Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world's leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.
› Verified 4 days ago